Statins Are Associated With a Decreased Risk of Severe Liver Disease in Individuals With Noncirrhotic Chronic Liver Disease

被引:10
|
作者
Sharma, Rajani [1 ,2 ,11 ]
Simon, Tracey G. [3 ]
Hagstrom, Hannes [4 ,5 ,6 ]
Lochhead, Paul [7 ]
Roelstraete, Bjorn [8 ]
Soderling, Jonas [3 ]
Verna, Elizabeth C. [1 ,2 ]
Emond, Jean [1 ]
Ludvigsson, Jonas F. [2 ,8 ,9 ,10 ]
机构
[1] Columbia Univ, Ctr Liver Dis & Transplantat, Div Digest & Liver Dis, Irving Med Ctr, New York, NY USA
[2] Columbia Univ, Dept Med, Div Digest & Liver Dis, Coll Phys & Surg, New York, NY USA
[3] Massachusetts Gen Hosp, Liver Ctr, Div Gastroenterol, Boston, MA USA
[4] Karolinska Univ Hosp, Ctr Digest Dis, Unit Hepatol, Stockholm, Sweden
[5] Karolinska Inst, Dept Med, Div Clin Epidemiol, Stockholm, Sweden
[6] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden
[7] GlaxoSmithKline PLC, London, England
[8] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[9] Orebro Univ Hosp, Dept Pediat, Orebro, Sweden
[10] Univ Nottingham, Sch Med, Div Epidemiol & Publ Hlth, Nottingham, England
[11] Columbia Univ, Ctr Liver Dis & Transplantat, Irving Med Ctr, 622 West 168th St,PH14,Suite 202, New York, NY 10032 USA
基金
瑞典研究理事会; 美国国家卫生研究院;
关键词
Cirrhosis; Hepatocellular Carcinoma; Fibrosis; CIRRHOSIS; DECOMPENSATION; REGISTER; COHORT;
D O I
10.1016/j.cgh.2023.04.017
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Little is known about the potential impact of statins on the progression of noncirrhotic chronic liver diseases (CLDs) to severe liver disease. METHODS: Using liver histopathology data in a nationwide Swedish cohort, we identi fi ed 3862 noncirrhotic individuals with CLD and statin exposure, de fi ned as a statin prescription fi lled for 30 or more cumulative de fi ned daily doses. Statin users were matched to 3862 (statin) nonusers with CLD through direct 1:1 matching followed by propensity score matching. Cox regression was used to estimate hazard ratios (HRs) for the primary outcome of incident severe liver disease (a composite of cirrhosis, hepatocellular carcinoma, and liver transplantation/liverrelated mortality). RESULTS: A total of 45.3% of CLD patients had nonalcoholic fatty liver disease, 21.9% had alcohol -related liver disease, 17.7% had viral hepatitis, and 15.1% had autoimmune hepatitis. During follow-up evaluation, 234 (6.1%) statin users vs 276 (7.1%) nonusers developed severe liver disease. Statin use was associated with a decreased risk of developing severe liver disease (HR, 0.60; 95% CI, 0.48 - 0.74). Statistically signi fi cantly lower rates of severe liver disease were seen in alcohol -related liver disease (HR, 0.30; 95% CI, 0.19 - 0.49) and in nonalcoholic fatty liver disease (HR, 0.68; 95% CI, 0.45 - 1.00), but not in viral hepatitis (HR, 0.76; 95% CI, 0.51 - 1.14) or autoimmune hepatitis (HR, 0.88; 95% CI, 0.48 - 1.58). Statin use had a protective association in both pre fi brosis and fi brosis stages at diagnosis. Statin use was associated with lower rates of progression to cirrhosis (HR, 0.62; 95% CI, 0.49 - 0.78), hepatocellular carcinoma (HR, 0.44; 95% CI, 0.27 - 0.71), and liver -related mortality (HR, 0.55; 95% CI, 0.36 - 0.82). CONCLUSIONS: Among individuals with noncirrhotic CLD, incident statin use was linked to lower rates of severe liver disease, suggesting a potential disease -modifying role.
引用
收藏
页码:749 / 759.e19
页数:30
相关论文
共 50 条
  • [21] Statins Associated With Decreased Risk of New Onset Inflammatory Bowel Disease
    Ungaro, Ryan
    Chang, Helena L.
    Cote-Daigneaut, Justin
    Mehandru, Saurabh
    Atreja, Ashish
    Colombel, Jean-Frederic
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (10): : 1416 - 1423
  • [22] Moderate to severe, but not mild, nonalcoholic fatty liver disease associated with increased risk of gallstone disease
    Lee, Yen-Chun
    Wu, Jin-Shang
    Yang, Yi-Ching
    Chang, Chin-Sung
    Lu, Feng-Hwa
    Chang, Chih-Jen
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2014, 49 (08) : 1001 - 1006
  • [23] Genetic algorithms identify individuals with high risk of severe liver disease caused by schistosomes
    Dessein, Helia
    Duflot, Nicolas
    Romano, Audrey
    Opio, Christopher
    Pereira, Valeria
    Mola, Carla
    Kabaterene, Narcis
    Coutinho, Ana
    Dessein, Alain
    HUMAN GENETICS, 2020, 139 (6-7) : 821 - 831
  • [24] Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease
    Hagstrom, Hannes
    Talback, Mats
    Andreasson, Anna
    Walldius, Goran
    Hammar, Niklas
    GASTROENTEROLOGY, 2020, 158 (01) : 200 - 214
  • [25] Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease
    Arvind, Ashwini
    Henson, Jacqueline B.
    Osganian, Stephanie A.
    Nath, Cheryl
    Steinhagen, Lara M.
    Memel, Zoe N.
    Donovan, Arley
    Balogun, Oluwafemi
    Chung, Raymond T.
    Simon, Tracey G.
    Corey, Kathleen E.
    HEPATOLOGY COMMUNICATIONS, 2022, 6 (02) : 309 - 319
  • [26] Use of statins in patients with liver disease
    Tandra S.
    Vuppalanchi R.
    Current Treatment Options in Cardiovascular Medicine, 2009, 11 (4) : 272 - 278
  • [27] Nonalcoholic fatty liver disease and statins
    Tziomalos, Konstantinos
    Athyros, Vasilios G.
    Paschos, Paschalis
    Karagiannis, Asterios
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2015, 64 (10): : 1215 - 1223
  • [28] Rationale for the use of statins in liver disease
    Schierwagen, Robert
    Uschner, Frank Erhard
    Magdaleno, Fernando
    Klein, Sabine
    Trebicka, Jonel
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2017, 312 (05): : G407 - G412
  • [29] Auxiliary Partial Orthotopic Liver Transplantation for Selected Noncirrhotic Metabolic Liver Disease
    Rammohan, Ashwin
    Reddy, Mettu S.
    Narasimhan, Gomathy
    Rajalingam, Rajesh
    Kaliamoorthy, Ilankumaran
    Shanmugam, Naresh
    Rela, Mohamed
    LIVER TRANSPLANTATION, 2019, 25 (01) : 111 - 118
  • [30] Metabolic Dysfunction-Associated Fatty Liver Disease, Statins, and Atherosclerotic Cardiovascular Disease
    Chang, Hui-Chin
    Gau, Shuo-Yan
    AMERICAN JOURNAL OF MEDICINE, 2024, 137 (01): : E14 - E14